Unmet needs in the treatment and care of somatic manifestations in mucopolysaccharidosis type II: A targeted literature review
Authors:
- Barbara K. BurtonBarbara K. Burton
- Daniel FertekDFDaniel Fertek
- Peter S. ChinPCPeter S. Chin
- Carole HoCHCarole Ho
- Roberto GiuglianiRoberto Giugliani
- Johanna M.P. van Den HoutJHJohanna M.P. van Den Hout
- Martin MagnerMMMartin Magner
- Fatih EzgüFEFatih Ezgü
- Moeenaldeen AlSayedMAMoeenaldeen AlSayed
- Joseph MuenzerJMJoseph Muenzer
- Simon A. JonesSJSimon A. Jones
Open Access
- 1 October 2025
- journal article
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 146 (3) , 109248
Abstract
No abstract availableKeywords
Funding Information
- Denali Therapeutics Inc
This publication has 152 references indexed in Scilit:
- Natural history of valve disease in patients with mucopolysaccharidosis II and the impact of enzyme replacement therapyJournal of Inherited Metabolic Disease, 2024
- Aortic root dilatation in patients with mucopolysaccharidoses and the impact of enzyme replacement therapyHeart and Vessels, 2018
- Development of a mnemonic screening tool for identifying subjects with Hunter syndromeEuropean Journal of Pediatrics, 2013
- Characterization of pulmonary function impairments in patients with mucopolysaccharidoses—changes with age and treatmentPediatric Pulmonology, 2013
- Improvements in Sensorineural Hearing Loss After Cord Blood Transplant in Patients With MucopolysaccharidosisJAMA Otolaryngology–Head & Neck Surgery, 2012
- Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfallsEuropean Journal of Pediatrics, 2012
- Mucopolysaccharidosis type II in females and response to enzyme replacement therapyAmerican Journal of Medical Genetics Part A, 2012
- The role of enzyme replacement therapy in severe Hunter syndrome—an expert panel consensusEuropean Journal of Pediatrics, 2011
- Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapyEuropean Journal of Pediatrics, 2007
- Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)American Journal of Medical Genetics Part A, 2005